This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
NeuroPace (NPCE) Q2 Earnings Beat, '24 Sales View Up
by Zacks Equity Research
NeuroPace's (NPCE) top and bottom lines outpace estimates in the second quarter.
Neuronetics (STIM) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Neuronetics (STIM) delivered earnings and revenue surprises of -22.22% and 12.29%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Avinger (AVGR) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Avinger (AVGR) delivered earnings and revenue surprises of -555.81% and 27.57%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Waters (WAT) Q2 Earnings and Revenues Top Estimates
by Zacks Equity Research
Waters (WAT) delivered earnings and revenue surprises of 3.14% and 1.51%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Globus Medical (GMED) Q1 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Globus Medical (GMED) delivered earnings and revenue surprises of 30.91% and 3.41%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Thermo Fisher Scientific (TMO) Tops Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Thermo Fisher (TMO) delivered earnings and revenue surprises of 1.62% and 1.35%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
RxSight, Inc. (RXST) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
RxSight, Inc. (RXST) delivered earnings and revenue surprises of 12.86% and 19.46%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Alphatec (ATEC) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Alphatec (ATEC) delivered earnings and revenue surprises of -9.38% and 3.18%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Accuray (ARAY) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Accuray (ARAY) delivered earnings and revenue surprises of -500% and 8.20%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Pulse Biosciences, Inc (PLSE) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Pulse Biosciences, Inc (PLSE) delivered earnings and revenue surprises of 0% and 52.17%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
908 Devices Inc. (MASS) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
908 Devices Inc. (MASS) delivered earnings and revenue surprises of 0% and 2.93%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Abiomed (ABMD) Q1 Earnings Top Estimates
by Zacks Equity Research
Abiomed (ABMD) delivered earnings and revenue surprises of 15.74% and 0.42%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Pulse Biosciences, Inc (PLSE) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
Pulse Biosciences, Inc (PLSE) delivered earnings and revenue surprises of 5.88% and 36.57%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Shockwave Medical (SWAV) Surpasses Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Shockwave Medical (SWAV) delivered earnings and revenue surprises of 105.26% and 5.74%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
LivaNova (LIVN) Lags Q1 Earnings Estimates
by Zacks Equity Research
LivaNova (LIVN) delivered earnings and revenue surprises of -7.69% and 3.09%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Pfizer (PFE) Q1 Earnings and Revenues Miss Estimates
by Zacks Equity Research
Pfizer (PFE) delivered earnings and revenue surprises of -2.41% and 3.14%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Meridian Bioscience and NeuroPace have been highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
Meridian Bioscience and NeuroPace have been highlighted as Zacks Bull and Bear of the Day.
Bear of the Day: NeuroPace (NPCE)
by Kevin Cook
EPS estimates get slashed 50% but sales still expected to grow for this innovative epilepsy device